## 3 Results
### Psychostimulant and Non-Psychostimulant Medication for ADHD  
Table 3 shows the comparative analysis of the evolution of the symptomatology frequency in the two groups, according to the type of medication administered, through the total mean scores obtained on the ADHD-RS scale by the subjects of group 1 versus group 2. Comparative Analysis of the ADHD-RS Scores between Group 1 with Psychostimulants and Group 2 with Non-Psychostimulants  
We compared the total mean scores obtained at baseline on the ADHD-RS scale by the patients in the two groups with those obtained at six months, one year, and two years after treatment (psychostimulant with Methylphenidate or non-psychostimulant with Atomoxetine). We have noticed that a significant reduction in overall mean scores has occurred in both groups. However, we found that total mean scores were significantly more reduced in the group treated with Psychostimulants. \(p<0.05\) was present in all three assessments performed since the start of treatment. The significant reduction in the frequency of ADHD symptoms is observed even six months after the treatment. The scores continue to decline significantly also at one and respectively, two years, after the treatment. In the non-psychostimulant treatment group (Atomoxetine), too, there was a significant reduction in total mean scores on the ADHD-RS from baseline to six months, one year, and two years after the start of treatment. Through the assessment of the efficacy of the drug treatment following the evolution over time of the scores obtained on the CGI-S scale, the statistical analysis did not reveal a significant difference between the total mean scores obtained on the CGI-S scale of the two groups (\(p\) greater than 0.05). However, it can be observed that the tendency to reduce the scores is higher in the group treated with psychostimulants. In this group, the scores dropped at six months and at one year post-treatment, while in group 2, the scores decreased only at six months after the treatment started. Comparative Analysis between Group 1 with Psychostimulants and Group 2, Concerning the CGI-S Scale Scores, in Different Time Points  
The severity assessment component of the CGI-S scale evaluates the degree of severity of the symptoms caused by ADHD (Table 4). \begin{table}
\begin{tabular}{c c c} \hline \hline
**ADHD Medication** & _Psychostimulant_ & _Non-psychostimulant_ \\ \hline _Methylphenidate_ & +++ & \\ _Amphetamines_ & +++ & \\ _Atomoxetine_ & & +++ \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Psychostimulant and non-psychostimulant medication for ADHD. \begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline
**ADHD Rating Scale** & \multicolumn{3}{c}{**Mean Total Scores Obtained in**} & \multicolumn{3}{c}{**Mean Total Scores Obtained in**} & \multicolumn{3}{c}{**Mean Total Scores Obtained in**} & \multirow{3}{*}{\(p\)} \\  & & **G1—Psychostimulants** & & & & **G2—Non-Psychostimulants** & \\ \hline
**Time Point** & \multirow{2}{*}{**Mean**} & **Std. Deviation** & \multirow{2}{*}{**Min.**} & \multirow{2}{*}{**Max.**} & \multirow{2}{*}{**Mean**} & **Std. Deviation** & \multirow{2}{*}{**Min.**} & \multirow{2}{*}{**Max.**} & **Sign** \\ \hline BASELINE & 41 & 2.92 & 16.00 & 25.00 & 39 & 2.11 & 15.00 & 23.00 & - \\
6 Months & 30 & 2.78 & 17.40 & 27.70 & 34 & 1.42 & 27.40 & 37.80 & 0.046 \\
1 Year & 25 & 1.93 & 23.80 & 30.00 & 30 & 1.20 & 17.40 & 27.78 & 0.007 \\
2 Years & 15 & 2.14 & 24.50 & 33.00 & 25 & 1.78 & 24.39 & 33.78 & 0.0001 \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Comparative analysis of the ADHD-RS scores between group 1 with psychostimulants and group 2 with non-psychostimulants. In the group treated with psychostimulants--Methylphenidate, we noted that there was a significant reduction in 6-month and respectively, one year scores (\(p\) = 0.049), after treatment (\(p\) = 0.049), followed by a plateau phase in which the total mean scores remain unchanged.